Ovarian serous cystadenocarcinoma

Changed by Craig Hacking, 30 May 2020

Updates to Article Attributes

Body was changed:

Ovarian serous cystadenocarcinoma is the malignant form of ovarian serous tumour, the most common type of ovarian epithelial tumour. It is the most common type of ovarian malignancy.

Increasingly, high-grade serous carcinoma and low-grade serous carcinoma are recognized as distinct tumour types rather than a spectrum of disease grade as implied by the nomenclature (see Pathology for more).

Terminology

Serous ovarian tumors are traditionally described with a "cyst-" prefix because of their primarily cystic composition, e.g. cystadenoma, cystadenocarcinoma.

Epidemiology

Account for the largest proportion of malignant ovarian tumours 1, representing over 50-80% of all malignant epithelial ovarian tumours 4. Serous ovarian cystadenocarcinomas account for ~25% of serous tumours.

The incidence peaks around the 6th to 7th decades of life 2

Pathology

Macroscopic appearance

  • multilocular cystic ovarian tumour with papillary projections

Microscopic appearance

  • classified as high-grade versus low-grade carcinoma 9:
    • high-grade serous carcinoma (HGSC)
      • common (70-80%)
      • thought to originate from distal fallopian tube epithelium 
      • high grade nuclear features (e.g. nuclear pleomorphism, abnormal mitotic figures)
      • characterized by intratumoral heterogeneity 
      • nearly ubiquitous p53 positivity 
    • low-grade serous carcinoma (LGSC)
      • uncommon (~5%) 9
      • thought to mostly represent malignant degeneration of serous cystadenoma 9
  • psammomatous bodies may be present in either LGSC or HGSC, but more numerous in LGSC 9
Risk factors

Recognised risk factors include:

  • nulliparity
  • early menarche 
  • late menopause
  • positive family history
  • infertility
Markers
Staging

See ovarian cancer staging.

Radiographic features

Imaging plays an important role in the diagnosis of ovarian tumors and in the assessment for metastatic disease. However, surgical evaluation is the standard of care for staging of disease.

Typical imaging features of ovarian cystadenocarcinoma include:

  • cystic adnexal mass with a substantial solid component
  • calcification uncommon, but can be seen (~12%) 4
    • also seen in serous cystadenoma and other tumours
  • frequently bilateral

In the setting of suspected ovarian cystadenocarcinoma, features suggestive of extra-ovarian metastasis include:

Ultrasound
  • mixed cystic/solid lesion
    • more heterogeneous than a serous cystadenoma
    • papillary projections, thick septations, and/or solid components
  • ascites
    • concerning for peritoneal metastatic spread
    • discrete peritoneal deposits may be seen
  • colour Doppler is useful to confirm vascularity of the solid components
CT

CT may be used for preoperative evaluation to assess for metastatic disease, e.g. peritoneal nodularity, ascites, or intrathoracic lesions.

MRI

MRI provides the most detailed imaging evaluation for ovarian malignancies, and may be used in either preoperative evaluation or post-treatment follow up.

  • T1
    • cystic portions are T1 dark, unless there has been intralesional hemorrhage (keep in mind mucinous tumors also have brighter T1 appearance in the cystic component)
    • solid portions are T1 intermediate
  • T2
    • cystic portions are T2 bright
    • solid portions are T2 intemediate
  • T1 C+: solid portions enhance
  • DWI/ADC
    • solid components restrict diffusion
    • metastases may exhibit restricted diffusion may The cystic components are high T2, low T1 signal unless there has been intralesional haemorrhage (c.f. , where there is typically slightly increased T1 signal of the cystic component).

See also

  • -<li>colour Doppler is useful to confirm vascularity of the solid components<ul><li>quantitative parameters (resistive index and pulsatility index) do not reliably predict malignancy</li></ul>
  • +<li>colour Doppler is useful to confirm vascularity of the solid components<ul><li>quantitative parameters (<a href="/articles/resistive-index-vascular-ultrasound">resistive index (RI)</a> and <a title="Pulsatility index (ultrasound)" href="/articles/pulsatility-index-ultrasound">pulsatility index (PI)</a>) do not reliably predict malignancy</li></ul>
  • -</ul><h5>CT</h5><p>CT may be used for preoperative evaluation to assess for metastatic disease, e.g. peritoneal nodularity, ascites, or intrathoracic lesions.</p><h5>MRI</h5><p>MRI provides the most detailed imaging evaluation for ovarian malignancies, and may be used in either preoperative evaluation or post-treatment follow up.</p><ul>
  • +</ul><h5>CT</h5><p>CT may be used for preoperative evaluation to assess for metastatic disease, e.g. peritoneal nodularity, ascites, or intrathoracic lesions.</p><h5>MRI</h5><p>MRI provides the most detailed imaging evaluation for ovarian malignancies and may be used in either preoperative evaluation or post-treatment follow up.</p><ul>

ADVERTISEMENT: Supporters see fewer/no ads

Updating… Please wait.

 Unable to process the form. Check for errors and try again.

 Thank you for updating your details.